Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

Provided are a pharmaceutical composition including reovirus or reovirus-treated biological sample as an active ingredient for prevention or treatment of cancer, and a method for prevention or treatment of cancer using same. In addition, provided are a combination use of the pharmaceutical composition and an immune checkpoint inhibitor for treatment of cancer.

Provided are a pharmaceutical composition including reovirus or reovirus-treated biological sample as an active ingredient for prevention or treatment of cancer, and a method for prevention or treatment of cancer using same. In addition, provided are a combination use of the pharmaceutical composition and an immune checkpoint inhibitor for treatment of cancer.

The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Disclosed in the present invention is a pharmaceutical composition, comprising: 1) a reagent for reducing bonding between an Fc receptor and an endogenous serum antibody, wherein the reagent comprises an immunoglobulin degrading enzyme or endo-glycosidase; and 2) a viral vector drug, wherein the viral vector drug is selected from an oncolytic virus and a viral vaccine. The pharmaceutical composition allows individual administration of the viral vector drug and the reagent. Further disclosed in the present invention are an application of the pharmaceutical composition in the preparation of a drug for treating or preventing disasters, and a method for applying the pharmaceutical composition to a subject to treat or prevent cancers or infections.

Disclosed in the present invention is a pharmaceutical composition, comprising: 1) a reagent for reducing bonding between an Fc receptor and an endogenous serum antibody, wherein the reagent comprises an immunoglobulin degrading enzyme or endo-glycosidase; and 2) a viral vector drug, wherein the viral vector drug is selected from an oncolytic virus and a viral vaccine. The pharmaceutical composition allows individual administration of the viral vector drug and the reagent. Further disclosed in the present invention are an application of the pharmaceutical composition in the preparation of a drug for treating or preventing disasters, and a method for applying the pharmaceutical composition to a subject to treat or prevent cancers or infections.

The present disclosure provides therapeutic agents comprising oncolytic vaccinia viruses and NK cells, and uses thereof for preparation of drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic vaccinia virus and NK cells, wherein the oncolytic vaccinia virus can selectively replicate in tumor cells.

The present disclosure provides therapeutic agents comprising oncolytic vaccinia viruses and NK cells, and uses thereof for preparation of drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic vaccinia virus and NK cells, wherein the oncolytic vaccinia virus can selectively replicate in tumor cells.

The present disclosure provides therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic virus that selectively replicate in tumor cells and comprise NK cells.